A new federal bill would expand and coordinate scientific research of cannabidiol (CBD) or marijuana-derived products, allowing researchers to better understand their potential efficacy and safety. While medical cannabis is increasingly available in a number of states nationwide, too often, there is little clinical data available to help patients and health care providers make informed decisions about whether it would work well for their specific condition, or how much and what type to use.

Introduced by Senators Dianne Feinstein, Chuck Grassley, and Brian Schatz, The Cannabidiol and Marihuana Research Expansion Act (S. 2032) would streamline the research process, eliminating the lengthy delays and roadblocks researchers face when trying to study medical marijuana and CBD-derived products.

Why U.S. Pain supports S. 2032

We believe people with chronic illness and pain should have access to all safe, effective treatments, including medical cannabis. Research is critical as it would lead to increased understanding about cannabis as a therapeutic option (including efficacy, safety, proper dosing, best delivery methods, etc.) and may lead to new, FDA-approved treatment options for people with pain.

Now is the time to take action

U.S. Pain has created two online campaigns for advocates on this issue because we’d like to accomplish two goals:

  1. Have the Senate Committee on the Judiciary schedule a hearing on the bill
  2. Gain additional cosponsors of the bill

Click here and see if your Senator sits on the Committee on the Judiciary. If they do, use the button below.

Urge your Senators to hold a hearing

If your Senator doesn’t sit on the committee, you can still help support medical marijuana and CBD research by requesting he/she becomes a cosponsor.

To learn more about U.S. Pain’s position on medical cannabis, click here.